Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trilaciclib - G1 Therapeutics

Drug Profile

Trilaciclib - G1 Therapeutics

Alternative Names: COSELA; G1T 28; G1T28-1

Latest Information Update: 02 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator G1 Therapeutics
  • Developer Boehringer Ingelheim; G1 Therapeutics; Quantum Leap Healthcare Collaborative; Simcere Pharmaceutical Group
  • Class Amines; Antineoplastics; Aza compounds; Chemoprotectants; Cyclohexanes; Ketones; Piperazines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Radioprotectives; Small molecules; Spiro compounds
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Myelosuppression; Small cell lung cancer
  • Phase III Colorectal cancer; Triple negative breast cancer
  • Phase II Bladder cancer; Breast cancer; Non-small cell lung cancer
  • No development reported Cancer

Most Recent Events

  • 01 Mar 2024 G1 Therapeutics terminates a phase II PRESERVE3 trial in Bladder cancer (Metastatic disease, First-line therapy, Combination therapy, Late-stage disease) in Georgia, Hungary, Spain, France, USA (IV) as the sponsor is no longer pursuing trial for the indication (NCT04887831)
  • 10 Jan 2024 G1 Therapeutics initiates enrolment in the phase II trial for Triple negative breast cancer (Combination therapy, Late-stage disease, Second-line therapy or greater, Metastatic disease, Inoperable/Unresectable) in USA (IV) (NCT06027268)
  • 08 Jan 2024 Efficacy data from a phase II trial in Triple negative breast cancer released by G1 Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top